The use of meloxicam oral suspension to treat musculoskeletal lameness in cattle

D Nagel,1 R Wieringa,2 J Ireland,3 Merle E Olson1 1Solvet/Alberta Veterinary Laboratories, Calgary, AB, 2Heartland Veterinary Services, Listowel, 3Albadon Farm Ltd, Teeswater, ON, Canada Abstract: Lameness in beef and dairy cattle is responsible for economic losses and has significant anima...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nagel D, Wieringa R, Ireland J, Olson ME
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Meloxicam Lameness Musculoskeletal Residue Milk Cattle Veterinary medicine SF600-1100
Acceso en línea:	https://doaj.org/article/a362d0157e7941dba1d1884ebe39d2dc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a362d0157e7941dba1d1884ebe39d2dc
record_format	dspace
spelling	oai:doaj.org-article:a362d0157e7941dba1d1884ebe39d2dc2021-12-02T00:33:38ZThe use of meloxicam oral suspension to treat musculoskeletal lameness in cattle2230-2034https://doaj.org/article/a362d0157e7941dba1d1884ebe39d2dc2016-11-01T00:00:00Zhttps://www.dovepress.com/the-use-of-meloxicam-oral-suspension-to-treat-musculoskeletal-lameness-peer-reviewed-article-VMRRhttps://doaj.org/toc/2230-2034D Nagel,1 R Wieringa,2 J Ireland,3 Merle E Olson1 1Solvet/Alberta Veterinary Laboratories, Calgary, AB, 2Heartland Veterinary Services, Listowel, 3Albadon Farm Ltd, Teeswater, ON, Canada Abstract: Lameness in beef and dairy cattle is responsible for economic losses and has significant animal welfare implications. It has been proposed that early treatment with analgesics not only reduces acute pain but also leads to reduced long-term sensitization. Fifty-three cattle (309–954 kg body weight [BW], mean: 656 kg) with musculoskeletal lameness were scored for lameness and inflammation, then randomly assigned to a single oral treatment with meloxicam oral suspension (MOS) (28 animals) at 1 mg/kg or saline at 1 mL/15 kg BW. Lameness and inflammation were reevaluated 3 days after treatment, and 26 of 28 (92.8%) MOS-treated animals had a reduced lameness score, while only three of 25 control animals had a reduced lameness score. MOS was effective in treating musculoskeletal disease in cattle. In an accompanying residue depletion study, 22 lactating Holstein cows (BW: 553–927 kg, mean: 713 kg) were used in the study. All 22 animals received MOS at the dose of 1 mg/kg BW once. Milk (500 mL sample from the full milking volume) was collected at approximately 48, 72, 96, and 120 hours after the treatment. Samples were subjected to in vitro analysis for quantification of meloxicam by liquid chromatography and mass spectroscopy. The mean meloxicam concentration at 48 and 72 hours were 30.75 and 2.82 ng/mL, respectively. The meloxicam milk concentration was below the limit of quantification (1 ng/mL) in 15 of 22 animals at 96 hours and in 22 of 22 animals at 120 hours. The milk meloxicam levels in all animals were below the maximum residue limit (Canada: 35 ng/mL; Europe: 15 ng/mL) at the 72-hour sampling. Keywords: meloxicam, lameness, musculoskeletal, residue, milk, cattle Nagel DWieringa RIreland JOlson MEDove Medical PressarticleMeloxicamLamenessMusculoskeletalResidueMilkCattleVeterinary medicineSF600-1100ENVeterinary Medicine: Research and Reports, Vol Volume 7, Pp 149-155 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Meloxicam Lameness Musculoskeletal Residue Milk Cattle Veterinary medicine SF600-1100
spellingShingle	Meloxicam Lameness Musculoskeletal Residue Milk Cattle Veterinary medicine SF600-1100 Nagel D Wieringa R Ireland J Olson ME The use of meloxicam oral suspension to treat musculoskeletal lameness in cattle
description	D Nagel,1 R Wieringa,2 J Ireland,3 Merle E Olson1 1Solvet/Alberta Veterinary Laboratories, Calgary, AB, 2Heartland Veterinary Services, Listowel, 3Albadon Farm Ltd, Teeswater, ON, Canada Abstract: Lameness in beef and dairy cattle is responsible for economic losses and has significant animal welfare implications. It has been proposed that early treatment with analgesics not only reduces acute pain but also leads to reduced long-term sensitization. Fifty-three cattle (309–954 kg body weight [BW], mean: 656 kg) with musculoskeletal lameness were scored for lameness and inflammation, then randomly assigned to a single oral treatment with meloxicam oral suspension (MOS) (28 animals) at 1 mg/kg or saline at 1 mL/15 kg BW. Lameness and inflammation were reevaluated 3 days after treatment, and 26 of 28 (92.8%) MOS-treated animals had a reduced lameness score, while only three of 25 control animals had a reduced lameness score. MOS was effective in treating musculoskeletal disease in cattle. In an accompanying residue depletion study, 22 lactating Holstein cows (BW: 553–927 kg, mean: 713 kg) were used in the study. All 22 animals received MOS at the dose of 1 mg/kg BW once. Milk (500 mL sample from the full milking volume) was collected at approximately 48, 72, 96, and 120 hours after the treatment. Samples were subjected to in vitro analysis for quantification of meloxicam by liquid chromatography and mass spectroscopy. The mean meloxicam concentration at 48 and 72 hours were 30.75 and 2.82 ng/mL, respectively. The meloxicam milk concentration was below the limit of quantification (1 ng/mL) in 15 of 22 animals at 96 hours and in 22 of 22 animals at 120 hours. The milk meloxicam levels in all animals were below the maximum residue limit (Canada: 35 ng/mL; Europe: 15 ng/mL) at the 72-hour sampling. Keywords: meloxicam, lameness, musculoskeletal, residue, milk, cattle
format	article
author	Nagel D Wieringa R Ireland J Olson ME
author_facet	Nagel D Wieringa R Ireland J Olson ME
author_sort	Nagel D
title	The use of meloxicam oral suspension to treat musculoskeletal lameness in cattle
title_short	The use of meloxicam oral suspension to treat musculoskeletal lameness in cattle
title_full	The use of meloxicam oral suspension to treat musculoskeletal lameness in cattle
title_fullStr	The use of meloxicam oral suspension to treat musculoskeletal lameness in cattle
title_full_unstemmed	The use of meloxicam oral suspension to treat musculoskeletal lameness in cattle
title_sort	use of meloxicam oral suspension to treat musculoskeletal lameness in cattle
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/a362d0157e7941dba1d1884ebe39d2dc
work_keys_str_mv	AT nageld theuseofmeloxicamoralsuspensiontotreatmusculoskeletallamenessincattle AT wieringar theuseofmeloxicamoralsuspensiontotreatmusculoskeletallamenessincattle AT irelandj theuseofmeloxicamoralsuspensiontotreatmusculoskeletallamenessincattle AT olsonme theuseofmeloxicamoralsuspensiontotreatmusculoskeletallamenessincattle AT nageld useofmeloxicamoralsuspensiontotreatmusculoskeletallamenessincattle AT wieringar useofmeloxicamoralsuspensiontotreatmusculoskeletallamenessincattle AT irelandj useofmeloxicamoralsuspensiontotreatmusculoskeletallamenessincattle AT olsonme useofmeloxicamoralsuspensiontotreatmusculoskeletallamenessincattle
_version_	1718403696376676352

The use of meloxicam oral suspension to treat musculoskeletal lameness in cattle

Ejemplares similares